The Effects of Acarbose on Non-Diabetic Overweight and Obese Patients: A Meta-Analysis

Yu, Alice L.; Le, Jiong; Huang, Wentao; Li, Bin; Liang, Huixin; Wang, Qun; Liu, Yuting; Young, C. W.; Zhang, Meiying; Qin, Shu-Lan

doi:10.1007/s12325-020-01602-9

Cited by 15 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings are consistent with the results of the meta-analysis study by Yu et al which reported that acarbose intake did not have a significant effect on FBS in non-diabetic obese and overweight individuals (Yu et al, 2021), Similarly, our study found that acarbose intake only had a significant effect on FBS in diabetics and impaired glucose tolerance patients and not in non-diabetic individuals, such as those with polycystic ovary syndrome. Given the World Health Organization's report that one-third of individuals with impaired glucose tolerance eventually develop diabetes within 10 years (Nijpels, Boorsma, Dekker, Kostense, Bouter & Heine, 2008), our findings suggest that the intake of acarbose with a dose of more than 300 mg/d for 6 months or more may improve glucose tolerance disorder and its progression towards T2DM.…”

Section: Discussionsupporting

confidence: 93%

A systematic review, meta-analysis, dose-response, and meta-regression of the effects of acarbose intake on glycemic markers in adults

Dehkordi

Pahlavani

Nikbaf-Shandiz

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Prior research has yielded mixed results regarding the impact of acarbose intake on glycemic markers. To provide a more comprehensive analysis, a systematic review and meta-analysis was performed to compile data from various randomized controlled trials (RCTs) examining the effects of acarbose intake on fasting blood sugar (FBS), insulin, hemoglobin A1C (HbA1c), and homeostasis model assessment of insulin resistance (HOMA-IR) in adults. Methods: To identify relevant literature up to April 2023, a comprehensive search was conducted on various scholarly databases, including PubMed, Web of Science, and Scopus databases. The effect size of the studies was evaluated using a random-effects model to calculate the weighted mean differences (WMD) and 95% confidence intervals (CI). Heterogeneity between studies was assessed using Cochran’s Q test and I2. Results: This systematic review and meta-analysis included a total of 101 RCTs with a total of 107 effect sizes. The effect sizes for FBS in milligrams per deciliter (mg/dl), insulin in picomoles per liter (pmol/l), hemoglobin A1C (HbA1c) in percentage (%), and homeostasis model assessment of insulin resistance (HOMA-IR) were 92, 46, 80, and 22, respectively. The pooled analysis indicated that acarbose intake resulted in significant decreases in FBS (p=0.018), insulin (p<0.001), HbA1c (p<0.001), and HOMA-IR (p<0.001). Conclusion: The findings of this systematic review and meta-analysis suggest that acarbose intake can potentially lead to significant improvements in glycemic indices by decreasing the levels of FBS, HbA1c, and insulin. However, larger and more rigorously designed studies are still needed to further evaluate and strengthen this association.

show abstract

Section: Discussionsupporting

confidence: 93%

A systematic review, meta-analysis, dose-response, and meta-regression of the effects of acarbose intake on glycemic markers in adults

Dehkordi

Pahlavani

Nikbaf-Shandiz

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In a study by Wu et al, among 272 patients with T2D, 80 patients who consumed 150 mg/day of ACB for 16 weeks showed a decrease in HbA1c% level by 2% compared with the initial level, which was in line with our result (120). In the recent meta-analysis conducted by Yu et al (24), the overall results from three studies involving 143 non-diabetic overweight or obese individuals (with a BMI of 25 kg/ m 2 ) did not show a significant reduction in FPG levels in the ACB group compared with the control group. These findings suggest that ACB treatment may not have a substantial impact on FPG levels in non-diabetic individuals with overweight or obesity (136).…”

Section: Discussionsupporting

confidence: 91%

“…Moreover, changes of body weight was significant between the ACB group and the group treated with ezetimibe, while BMI was not. In a recent meta-analysis study by Yu et al, overall, the results from five studies on 164 non-diabetic obese and overweight populations demonstrated that there was no significant difference in the outcome between the ACB group compared with the control group ( 24 ).…”

Section: Discussionmentioning

confidence: 99%

“…A meta-analysis of seven studies conducted by Yu et al provided evidence supporting the beneficial effect of acarbose (ACB) therapy in reducing triglyceride (TG) levels among non-diabetic patients who are overweight or obese. This suggests the potential usefulness of ACB in managing TG levels in this population (24). Another study by Schnell et al pooled the data from 10 previous studies and concluded that ACB treatment can reduce body weight independent of glycemic control in patients with diabetes (25).…”

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

The effects of acarbose treatment on cardiovascular risk factors in impaired glucose tolerance and diabetic patients: a systematic review and dose–response meta-analysis of randomized clinical trials

Zamani,

Nikbaf-Shandiz,

Aali

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

Acarbose (ACB) seems to be an effective drug in the management of cardiovascular risk factors. However, no previous meta-analysis of randomized controlled trials (RCTs) has been done to evaluate the effects of ACB on cardiovascular risk factors on impaired glucose tolerance (IGT), type 2 diabetes mellitus (T2D), and type 1 diabetes mellitus (T1D). We comprehensively searched electronic databases including Scopus, Web of Science, and PubMed for RCTs for related keywords up to September 2022. A random-effects model was used to estimate the weighted mean difference (WMD) and 95% confidence interval (CI). The pooled analysis demonstrated that ACB treatment had a significant effect on fasting blood glucose (FBG) (WMD = −3.55 mg/dL; 95%CI: −6.29, −0.81; p = 0.011), fasting insulin (WMD = −6.73 pmoL/L; 95%CI: −10.37, −3.10; p < 0.001), HbA1c [WMD = −0.32%; 95%CI: −0.45, −0.20; p < 0.001], body weight (WMD = −1.25 kg; 95%CI: −1.79, −0.75; p < 0.001), body mass index (BMI) (WMD = −0.64 kg/m2; 95%CI: −0.92, −0.37; p < 0.001), tumor necrosis factor-alpha (TNF-α) (WMD = −2.70 pg/mL, 95%CI: −5.25, −0.16; p = 0.037), leptin (WMD = −1.58 ng/mL; 95%CI: −2.82, −0.35; p = 0.012), alanine transaminase (ALT) (WMD = 0.71 U/L; 95%CI: −0.31, 1.85; p = 0.164), triglyceride (TG) (WMD = −13.89 mg/dL; 95%CI: −20.69, −7.09; p < 0.001), total cholesterol (TC) (WMD = −2.26 mg/dL; 95%CI: −4.18, −0.34; p = 0.021), systolic blood pressure (SBP) (WMD = −1.29 mmHg; 95%CI: −2.44, −0.15; p = 0.027), and diastolic blood pressure (DBP) (WMD = 0.02 mmHg; 95%CI: −0.41, 0.45; p = 0.925) in an intervention group, compared with a placebo group. The non-linear dose–response analysis showed that ACB reduces the TC in trial duration by >50 weeks, and 180 mg/day is more effective for the decrement of CRP. ACB can improve lipid profiles, glycemic indices, anthropometric indices, and inflammatory markers in T2D, T1D, and IGT patients.

show abstract

“…It has been studied both alone and in combination with orlistat in non-diabetic obese subjects, and GERD was not reported amongst adverse events. [66][67][68] Our searches returned no studies directly examining the effect *Not FDA-approved for the treatment of obesity.…”

Section: Non-fda Approved Medicationsmentioning

confidence: 99%

Medical Management of Obesity as it Affects Reflux

Haddad

Shah

2021

Foregut: The Journal of the American Foregut Society

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GERD) is common among the American population and increasing in prevalence, with obesity being implicated as one of the strongest risk factors for its development. Little is known about the effects of currently prescribed anti-obesity medications on GERD symptoms. This review aims to explore the current literature on FDA-approved and off-label anti-obesity pharmacotherapy with respect to their influence on GERD and interactions with commonly prescribed GERD medications.

show abstract

The Effects of Acarbose on Non-Diabetic Overweight and Obese Patients: A Meta-Analysis

Cited by 15 publications

References 27 publications

A systematic review, meta-analysis, dose-response, and meta-regression of the effects of acarbose intake on glycemic markers in adults

A systematic review, meta-analysis, dose-response, and meta-regression of the effects of acarbose intake on glycemic markers in adults

The effects of acarbose treatment on cardiovascular risk factors in impaired glucose tolerance and diabetic patients: a systematic review and dose–response meta-analysis of randomized clinical trials

Medical Management of Obesity as it Affects Reflux

Contact Info

Product

Resources

About